The Journal of Immunology, Vol 151, Issue 9 4782-4789, Copyright © 1993 by American Association of Immunologists

ARTICLES

Protective immunity in baboons vaccinated with a recombinant antigen or radiation-attenuated cercariae of Schistosoma mansoni is antibody- dependent

LA Soisson, GD Reid, IO Farah, M Nyindo and M Strand
Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205.

Mice vaccinated with radiation-attenuated cercariae of Schistosoma mansoni exhibit high levels of resistance to challenge infection. We have previously shown that sera from these mice recognize polypeptides that are expressed on the surface of newly transformed schistosomula. We have cloned and sequenced a cDNA that encodes a 62-kDa portion of one of these polypeptides. Vaccination of mice with this 62-kDa polypeptide (designated rlrV-5) elicits high antibody titers and significant resistance to challenge infection. We report here the results of a vaccination trial in baboons with the rlrV-5 or radiation- attenuated cercariae. rlrV-5 was presented either in the form of protein micelles or complexed with the outer membrane protein of meningococcus to form proteosomes. The level of protection achieved in these groups ranged from 0 to 54%, with a mean of 27.7%. In baboons exposed to radiation-attenuated cercariae the level of protection was very high, with a mean of 84%. The resistance observed after vaccination with rlrV-5 or radiation-attenuated cercariae was reflected in the overall histopathology. Vaccination of baboons with rlrV-5 or radiation-attenuated cercariae elicited an antibody response against epitopes exposed on the surface of newly transformed schistosomula. In the case of baboons vaccinated with radiation-attenuated cercariae, this response was not limited to epitopes encompassed by rlrV-5. Analysis of individual baboon sera by ELISA demonstrated that there was a direct correlation between the anti-rlrV-5 titer and resistance to challenge worm burden, suggesting that the immunoprotective mechanism is antibody-dependent.

This article has been cited by other articles:

				T. M. Kariuki, G. J. Van Dam, A. M. Deelder, I. O. Farah, D. S. Yole, R. A. Wilson, and P. S. Coulson Previous or Ongoing Schistosome Infections Do Not Compromise the Efficacy of the Attenuated Cercaria Vaccine Infect. Immun., July 1, 2006; 74(7): 3979 - 3986. [Abstract] [Full Text] [PDF]

				S. L. Hooper and J. B. Thuma Invertebrate Muscles: Muscle Specific Genes and Proteins Physiol Rev, July 1, 2005; 85(3): 1001 - 1060. [Abstract] [Full Text] [PDF]

				T. M. Kariuki, I. O. Farah, D. S. Yole, J. M. Mwenda, G. J. Van Dam, A. M. Deelder, R. A. Wilson, and P. S. Coulson Parameters of the Attenuated Schistosome Vaccine Evaluated in the Olive Baboon Infect. Immun., September 1, 2004; 72(9): 5526 - 5529. [Abstract] [Full Text] [PDF]

				M. Eberl, J. A. M. Langermans, P. A. Frost, R. A. Vervenne, G. J. van Dam, A. M. Deelder, A. W. Thomas, P. S. Coulson, and R. A. Wilson Cellular and Humoral Immune Responses and Protection against Schistosomes Induced by a Radiation-Attenuated Vaccine in Chimpanzees Infect. Immun., September 1, 2001; 69(9): 5352 - 5362. [Abstract] [Full Text] [PDF]

				A. Ribeiro de Jesus, I. Araujo, O. Bacellar, A. Magalhaes, E. Pearce, D. Harn, M. Strand, and E. M. Carvalho Human Immune Responses to Schistosoma mansoni Vaccine Candidate Antigens Infect. Immun., May 1, 2000; 68(5): 2797 - 2803. [Abstract] [Full Text] [PDF]

				T. Ben-Yedidia, R. Tarrab-Hazdai, D. Schechtman, and R. Arnon Intranasal Administration of Synthetic Recombinant Peptide-Based Vaccine Protects Mice from Infection by Schistosoma mansoni Infect. Immun., September 1, 1999; 67(9): 4360 - 4366. [Abstract] [Full Text] [PDF]

				M. Nyindo, T. M. Kariuki, P. W. Mola, I. O. Farah, L. Elson, R. E. Blanton, and C. L. King Role of Adult Worm Antigen-Specific Immunoglobulin E in Acquired Immunity to Schistosoma mansoni Infection in Baboons Infect. Immun., February 1, 1999; 67(2): 636 - 642. [Abstract] [Full Text] [PDF]